Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk

Prostate

Volumn 65, Issue 1, 2005, Pages 58-65

  Salinas, Claudia A ^a,b   Austin, Melissa A ^b   Ostrander, Elaine O ^a   Stanford, Janet L ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen receptor gene; APS gene; CAG repeats; Case control studies; Epidemiology; Odds ratio; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BODY MASS; CANCER GRADING; CANCER RISK; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; DNA DETERMINATION; FAMILY HISTORY; GENETIC POLYMORPHISM; HORMONE RESPONSE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROSTATE CANCER; TRANSACTIVATION;

ADULT; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK; TRINUCLEOTIDE REPEATS;

EID: 24944479088     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20230     Document Type: Article

References (44)

1. Smith P, Pavone-Macaluso M, editors. Reconstructive surgery, organ conservation, and restoration function. Wiley Liss: New York; 1991. p 418.
2. Wu CP, Gu FL. The prostate in eunuchs. Prog Clin Biol Res 1991;370:249-255.
3. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997-1007.
4. Stearns M, McGarvey T. Prostate cancer: Therapeutic, diagnostic and basic studies. Lab Invest 1992;67:540-552.
5. Shirai T, Takahashi S, Cui L, Futakuchi M, Kato K, Tamano S, Imaida K. Experimental prostate carcinogenesis-rodent models. Mutat Res 2000;462:219-226.
6. Gann P, Hennekens C, Ma J, Longcope C, Stampfer M. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-1126.
7. Ding D, Xu L, Menon M, Reddy GPV, Barrack ER. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 2005;62:133-139.
8. Chamberlain N, Driver E, Miesfield R. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affects transactivation function. Nucl Acids Res 1994;22:3181-3186.
9. Ding D, Xu L, Menon M, Reddy GPV, Barrack ER. Effect of a short CAG (Glutamine) repeat on human androgen receptor function. Prostate 2004;58:23-32.
10. n-expanded neuropathies. Hum Mol Genet 1995;4:523-527.
11. Tut T, Ghadessy F, Trifiro M, Pinsky L, Yong E. Long polyglutamine tracts in the androgen receptor are associated with reduced transactivation, impaired sperm production, and male infertility. J Clin Endocrin Metab 1997;82:3777-3782.
12. Giovanucci E, Stampfer M, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens C, Kantoff P. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320-3323.
13. Hsing A, Gao Y-T, Wu G, Wang X, Deng J, Chen Y-L, Sesterhenn I, Mostofi F, Benichou J, Chang C. Polymorphic CAG and GGN repeats lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China. Cancer Res 2000;60:5111-5116.
14. Xue W, Irvine R, Yu M, Ross R, Coetzee G, Ingles S. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific loci. Cancer Res 2000;60:839-841.
15. Gao T, Marcelli M, McPhaul MJ. Transcriptional activation and transient expression of the human androgen receptor. J Steroid Biochem Mol Biol 1996;59:9-20.
16. Cleutjens K, van Eekelen C, van der Korput H, Brinkmann A, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996;271:6379-6388.
17. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 1997;11:1256-1265.
18. Cramer S, Chang B, Rao A, Hawkins G, Zheng S, Wade W, Cooke R, Thomas L, Bleecker E, Catalona W, Sterline D, Meyers D, Ohar J, Xu J. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 2003;95:1044-1053.
19. Xue W, Coetzee G, Ross R, Irvine R, Kolonel L, Henderson B, Ingles S. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2001;10:575-579.
20. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57:1194-1198.
21. Harlow B, Davis S. Two one-step methods for household screening and interviewing using random digit dialing. Am J Epid 1988;127:857-863.
22. Breslow N, Day N. The analysis of case-control studies. Statistical methods in cancer research. Vol. 1. Lyons, France: IARC Scientific Publications; 1980.
23. Dubin N, Pasternack B. Risk assessment for case-control subgroups by polychotomous logistic regression. Am J Epidemiol 1986;123:1101-1117.
24. Bratt O, Borg XX, Kristoffersson U, Lundgren R, Zhang Q-X, Olsson H. 1999. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine theraphy, but not to prostate cancer risk. Br J Cancer 81:672-676.
25. nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 1999;7:357-362.
26. Edwards S, Badzioch M, Minter R, Hamoudi R, Collins N, Ardern-Jones A, Dowe A, Osborne S, Kelly J, Shearer R, Easton D, Saunders G, Dearnaley D, Eeles R. Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival. Int J Cancer (Fred Oncol) 1999;84:458-465.
27. Beilin J, Ball E, Favaloro J, Zajac J. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: Specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000;25:85-96.
28. Lange E, Chen H, Brierley K, Livermore H, Wojno K, Langefeld C, Lange K, Cooney K. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:439-442.
29. Latil A, Azzouri R, Cancel G, Guillaume E, Cochan-Priollet B, Berthon P, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130-1137.
30. Chen C, Lamharzi N, Weiss N, Etzioni R, Dightman D, Barnett M, DiTommaso D, Goodman G. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1033-1040.
31. Gsur A, Preyer M, Haidinger G, Zidek T, Madersbacher S, Schatzl G, Marberger M, Vutuc C, Micksche M. Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism, and prostate cancer risk. Carcinogenesis 2002;23:1647-1651.
32. Irvine R, Yu M, Coetzee G. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937-1940.
33. Ingles S, Ross R, Yu M, Irvine R, LaPera G, Haile R, Coetzee G. Association of prostate cancer risk with genetic polymorphisms in vitamine D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-170.
34. Platz E, Giovanucci E, Dahl D, Krithivas K, Hennekens C, Brown M, Stampfer M, Kantoff P. 1998. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:379-384.
35. Chang B, Zheng S, Hawkins G, Isaacs S, Wiley K, Turner A, Carpten J, Bleecker E, Walsh P, Trent J, Meyers D, Isaacs W, Xu J. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet 2002;110:122-129.
36. Rothman KJ, Poole C. A strengthening programme for weak associations. Int J Epidemiol 1988;17:955-959.
37. Stanford J, Just J, Gibbs M, Wickland K, Neal C, Blumenstein B, Ostrander E. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk. Cancer Res 1997;57:1194-1198.
38. Beilin J, Harewood L, Frydenberg M, Mameghan H, Martyres R, Farish S, Yue C, Deam D, Byron K, Zajac J. A case-control study of the androgen receptor gene polymorphism in Australian prostate carcinoma subjects. Cancer 2001;92:941-949.
39. Xu J, Meyers DA, Sterling DA, Zheng SL, Catalona WJ, Cramer SD, Bleecker ER, Ohar J. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 2002;11:664-669.
40. Rao A, Chang BL, Hawkins G, Hu JJ, Rosser CJ, Hall MC, Meyers DA, Xu J, Cramer SD. Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology 2003;61:864-869.
41. Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L, Lieber M, Cespedes R, Atkins J, Lippman S, Carline S, Ryan A, Szczepanek C, Crowley J, Coltman C. The influence of finasteride on the development of prostate cancer. New Engl J Med 2003;394:211-220.
42. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics 2003. CA Cancer J Clin 2003;53:5-26.
43. Snoek R, Bruchovsky N, Kasper S, Matusik R, Cleave M, Sato N, Mawji N, Rennie P. 1998. Differential transactivation by the androgen receptor in prostate cancer cells. The Prostate 1998;36:256-263.
44. Han G, Foster B, Mistry S, Buchanan G, Harris J, Tilley W, Greenberg N. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 2002;276:11204-11213.